Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population

Abnormally invasive placenta (AIP) is defined as an abnormal placental attachment of a part or the entire chorionic plate with penetration of chorionic villi in the myometrium and absence of the decidua basalis. This anomaly is associated with significant maternal morbidity and mortality as it may result in severe haemorrhage during the post-partum. It has been demonstrated that prenatal diagnosis of AIP is essential to reduce maternal morbidity. In a recent study of Chantraine F. et al. prenatal diagnosis of AIP leads to better outcomes, due to fewer emergency operations and less mass transfusions. Currently, the diagnosis of AIP is based on a combination of conventional B-mode ultrasound and MRI. However, prenatal diagnosis of AIP remains challenging and recent reports demonstrated it is achieved in only thirds of cases.

Contrast enhanced ultrasound (CEUS) is a non-invasive technique based on the detection by ultrasound (US) of gas-filled microbubbles used as perfusion tracers. Intravascular rheological properties of these bubbles are similar to those of red blood cells and they remain entirely within the intravascular space. Previous studies have demonstrated that microbubbles do not transfer into fetal circulation. CEUS has been used for years in many US imaging applications (e.g. liver, kidneys and breast). In obstetrics, despite not yet approved for clinical use, CEUS offers the opportunity to analyze anatomical placental landmarks, improving the contrast between placenta and myometrium. In addition, quantification parameters related to the contrast enhancement have been proposed as objective indicators to estimate blood perfusion rates in the placental intervillous space.

The main objective of this study is to provide pre-clinical evaluation of CEUS for the diagnosis of AIP and to try to determine if AIP are characterised by differences in intervillous blood rheological properties. Conventional CEUS parameters will be: rise time, peak enhancement, wash-in rate, mean transit time and wash-in area under the curve.

As this study is a pre-clinical evaluation, sample size calculation remains subjective and imprecise. For this reason, a sample size of 100 pregnant women to be included in this prospective study has been decided.

The potential impact of this study will be to propose a more reliable tool with both improved sensibility and specificity compared to the combination US/MRI and therefore to reduce the maternal worldwide burden of AIP.

Study Overview

• Status: Completed
• Conditions: Placenta Accreta
• Intervention / Treatment: Drug: contast-enhanced ultrasound with sonovue

• Study Type: Interventional
• Enrollment (Actual): 80
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Poitiers, France, 86000
    • CHU La Millétrie
  • Tours, France, 37044
    • University hospital of Tours

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Pregnant patient having any of the following two conditions:

  • Scar uterus (previous cesarean) with placenta previa partly or wholly on the uterine scar
  • Placenta praevia and patient aged over 35 years
• Term > 34 weeks of amenorrhea
• More than 18 years old
• Inform consent form signed
• affiliated to medical insurrance

Exclusion Criteria:

• Inability to understand information
• Contraindications to the contrast medium Sonovue:

• Hypersensitivity to hexafluorinated sulphur or any other components of Sonovue

  • Recent acute coronary syndrome (within 6 months before the intervention)
  • Unstable ischemic heart disease (myocardial infarction being formed or evolving, typical angina of rest in the previous month)
  • Significant worsening of cardiac symptoms between the pre anaesthesia consultation and intervention
  • Recent intervention (less than 6 months) on coronary arteries or other factor suggesting clinical instability (changes in ECG, changes in clinical or biological parameters)
  • Acute heart failure or heart failure stage III or IV
  • Severe arrhythmias
  • Right-left shunt
  • Acute endocarditis
  • Valve prothesis
  • Severe pulmonary hypertension (pulmonary artery pressure > 90mmHg)
  • Systemic hypertension uncontrolled
  • Respiratory distress syndrome

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: placenta accreta; contast-enhanced ultrasound with sonovue	Drug: contast-enhanced ultrasound with sonovue; contast-enhanced ultrasound with sonovue; Other Names: Sonovue® (Bracco, Milan, Italie)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Conventional contrast enhanced ultrasound parameters for diagnosing placenta accreta	up to 9 months after consent

Secondary Outcome Measures

Outcome Measure	Time Frame
depth of infiltration placenta measured by CEUS	up to 9 months after consent

Collaborators and Investigators

• Sponsor: University Hospital, Tours
• Investigators: Principal Investigator: Franck Perrotin, MD, University hospital of Tours

Publications and helpful links

General Publications

• Denis de Senneville B, Novell A, Arthuis C, Mendes V, Dujardin PA, Patat F, Bouakaz A, Escoffre JM, Perrotin F. Development of a Fluid Dynamic Model for Quantitative Contrast-Enhanced Ultrasound Imaging. IEEE Trans Med Imaging. 2018 Feb;37(2):372-383. doi: 10.1109/TMI.2017.2743099. Epub 2017 Aug 29.

Study record dates

Study Major Dates

• Study Start: May 1, 2009
• Primary Completion (Actual): May 1, 2016
• Study Completion (Actual): August 1, 2016

Study Registration Dates

• First Submitted: November 14, 2014
• First Submitted That Met QC Criteria: November 24, 2014
• First Posted (Estimated): November 27, 2014

Study Record Updates

• Last Update Posted (Actual): December 26, 2025
• Last Update Submitted That Met QC Criteria: December 18, 2025
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Keywords: MRI; pregnancy; placenta accreta; contrast-enhanced unltrasound; sonovue
• Additional Relevant MeSH Terms: Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Obstetric Labor Complications; Pregnancy Complications; Placenta Diseases; Placenta Accreta; contrast agent BR1
• Other Study ID Numbers: PHRI08-FP : Placenta Accreta